-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 27, it was reported that Suzhou Omini Pharmaceutical Co.
, Ltd.
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, announced the completion of the D round of hundreds of millions of yuan in financing.
This round of financing is funded by the Shanghai Biomedical Fund.
Leading investors, Bank of China Investment (BOCGI), Taikun Capital, Yuanlai Capital, Zhongxin Capital, and Zhangke Herun followed the investment
.
The funds raised from the financing will be used for the advancement of clinical research and R&D pipelines of multiple projects, as well as commercial operations
.
Asthma and COPD are major respiratory diseases, and there is a large demand for clinical medications
.
Data in 2019 show that the total number of adults with asthma in China reached 45.
7 million, and the total number of adults with COPD was nearly 100 million
.
Since the symptoms of asthma/COPD have a great impact on survival, and drugs can alleviate and control symptoms, there is a large demand for clinical medication in the asthma/COPD medication market
.
According to IQVIA data, the global asthma and COPD medication market has exceeded 52.
5 billion U.
S.
dollars in 2018, of which inhaled preparations reached 43.
7 billion U.
S.
dollars, accounting for 83.
2%
.
Looking at the domestic market, China’s asthma and COPD market was worth US$2.
3 billion in 2018, of which the market for inhaled preparations accounted for only 65.
5%, which was 20.
6% lower than the 86.
1% in Europe and America
.
With the maturity of medical conditions, the improvement of the public's awareness of diseases, and the more reasonable treatment methods, the penetration rate of the domestic inhalation preparation market is expected to further increase, and the market scale of asthma and COPD will continue to expand
.
According to data, Omini Pharmaceuticals was established in 2011.
Its R&D center is located in Shanghai Zhangjiang Medicine Valley, and its two production bases are located in Suzhou and Haimen, Jiangsu
.
As one of the few domestic pharmaceutical companies that have entered the field of respiratory inhalation preparations, Omini has many advantages in preparation R&D and device design.
.
At present, the company's research products cover all the key varieties in the field of respiratory inhalation preparations.
It has not only realized the independent research and development and production of the four major inhalation formulations of aerosols, powder mists, atomized solutions, and nasal sprays, but also established a market that meets international standards.
The standard technology platform also has an independent research and development platform for supporting breathing devices, covering blister powder aerosol devices, capsule powder aerosol devices, storage powder aerosol devices and breath-driven aerosol devices
.
Many of the company's projects are gradually entering phase III clinical trials, which will bring China's self-developed international-level respiratory preparations to the domestic market
.
It is worth mentioning that Omini Pharmaceuticals has also actively expanded the international market in recent years, and has joined hands with large international pharmaceutical companies to jointly develop European and American markets
.
For example, in February 2020, Omini Pharmaceuticals announced that it has reached a cooperation agreement with a large Indian pharmaceutical company active in the world, especially in the European and American markets.
The two parties will work together to develop an inhalation powder product, which will target the United States, Europe, and Canada.
The tens of billions of dollars market in the field of COPD asthma
.
Omini Pharmaceuticals will be responsible for the development and production of this product
.
Since its inception, Omini Medicine has received support from large international investment institutions such as Morningside Ventures, Lilly Asia Ventures (LAV), Vivo Capital, SDIC Ventures, and Yuansheng Ventures
.
According to reports, after years of development, Omini Pharmaceuticals has a very solid product pipeline and already has the ability to commercialize production and sales.
In the next three years, 2-3 products will be approved for marketing each year
.
, Ltd.
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, announced the completion of the D round of hundreds of millions of yuan in financing.
This round of financing is funded by the Shanghai Biomedical Fund.
Leading investors, Bank of China Investment (BOCGI), Taikun Capital, Yuanlai Capital, Zhongxin Capital, and Zhangke Herun followed the investment
.
The funds raised from the financing will be used for the advancement of clinical research and R&D pipelines of multiple projects, as well as commercial operations
.
Asthma and COPD are major respiratory diseases, and there is a large demand for clinical medications
.
Data in 2019 show that the total number of adults with asthma in China reached 45.
7 million, and the total number of adults with COPD was nearly 100 million
.
Since the symptoms of asthma/COPD have a great impact on survival, and drugs can alleviate and control symptoms, there is a large demand for clinical medication in the asthma/COPD medication market
.
According to IQVIA data, the global asthma and COPD medication market has exceeded 52.
5 billion U.
S.
dollars in 2018, of which inhaled preparations reached 43.
7 billion U.
S.
dollars, accounting for 83.
2%
.
Looking at the domestic market, China’s asthma and COPD market was worth US$2.
3 billion in 2018, of which the market for inhaled preparations accounted for only 65.
5%, which was 20.
6% lower than the 86.
1% in Europe and America
.
With the maturity of medical conditions, the improvement of the public's awareness of diseases, and the more reasonable treatment methods, the penetration rate of the domestic inhalation preparation market is expected to further increase, and the market scale of asthma and COPD will continue to expand
.
According to data, Omini Pharmaceuticals was established in 2011.
Its R&D center is located in Shanghai Zhangjiang Medicine Valley, and its two production bases are located in Suzhou and Haimen, Jiangsu
.
As one of the few domestic pharmaceutical companies that have entered the field of respiratory inhalation preparations, Omini has many advantages in preparation R&D and device design.
.
At present, the company's research products cover all the key varieties in the field of respiratory inhalation preparations.
It has not only realized the independent research and development and production of the four major inhalation formulations of aerosols, powder mists, atomized solutions, and nasal sprays, but also established a market that meets international standards.
The standard technology platform also has an independent research and development platform for supporting breathing devices, covering blister powder aerosol devices, capsule powder aerosol devices, storage powder aerosol devices and breath-driven aerosol devices
.
Many of the company's projects are gradually entering phase III clinical trials, which will bring China's self-developed international-level respiratory preparations to the domestic market
.
It is worth mentioning that Omini Pharmaceuticals has also actively expanded the international market in recent years, and has joined hands with large international pharmaceutical companies to jointly develop European and American markets
.
For example, in February 2020, Omini Pharmaceuticals announced that it has reached a cooperation agreement with a large Indian pharmaceutical company active in the world, especially in the European and American markets.
The two parties will work together to develop an inhalation powder product, which will target the United States, Europe, and Canada.
The tens of billions of dollars market in the field of COPD asthma
.
Omini Pharmaceuticals will be responsible for the development and production of this product
.
Since its inception, Omini Medicine has received support from large international investment institutions such as Morningside Ventures, Lilly Asia Ventures (LAV), Vivo Capital, SDIC Ventures, and Yuansheng Ventures
.
According to reports, after years of development, Omini Pharmaceuticals has a very solid product pipeline and already has the ability to commercialize production and sales.
In the next three years, 2-3 products will be approved for marketing each year
.
